Trials / Terminated
TerminatedNCT00712491
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Santen Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus | Three subconjunctival injections of 1320 micrograms sirolimus each. |
| DRUG | Sirolimus | Three intravitreal injections of 352 micrograms sirolimus each. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-11-01
- Completion
- 2010-03-01
- First posted
- 2008-07-10
- Last updated
- 2013-01-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00712491. Inclusion in this directory is not an endorsement.